riskguard™

Hereditary Cancer Test

UNDERSTANDING THE DIVERSE RISKS OF INHERITED CANCER SUSCEPTIBILITY

Exact Sciences has acquired PreventionGenetics, adding an established hereditary multi-cancer panel to a growing portfolio of oncology tests throughout the care continuum.

Riskguard™ detects germline variants to **help guide treatment planning and reveal hereditary cancer risk**. Equip yourself with another tool to help personalize your patient's treatment plan and provide insights into familial cancer risk and screening requirements.

IDENTIFY HEREDITARY CANCER RISK TO HELP PERSONALIZE TREATMENT

A multi-cancer panel that identifies germline variants, which may impact clinical decision-making in breast, prostate, colorectal, ovarian, endometrial, pancreatic, gastric, and melanoma cancers

CLINICALLY ACTIONABLE

Analyzes and focuses on 32 high-risk, clinically actionable genes informed by professional guidelines for patient management.*

INDIVIDUALIZED REPORT

Delivers clear results in an easy-to-understand report, including: risks for patients, risks for family members, and care options to help support treatment discussions.

PARTNER YOU CAN TRUST

Offers access to genetic counseling and world-class customer service to physicians, patients, and family members for a smooth experience.

HELPING IMPROVE LIVES THROUGH GENETIC TESTING

The combination of PreventionGenetics' leading genetics laboratory with Exact Sciences' customer service makes obtaining actionable genetic information a seamless process.

- Receive turnaround times (TAT) that meet your needs (approximately 18 calendar days)†
- Leverage PhDs to review current literature to maintain the relevance and actionability of genetic testing
- Experience a transformation in cancer care with simplified access to genetic testing and valuable insights

*Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic. V2.2022 and Genetic/Familial High-Risk Assessment: Colorectal. V.2.2022. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed August 1, 2022. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

†Data on file.

THE RISKGUARD™ 32-GENE HEREDITARY MULTI-CANCER TEST HELPS PERSONALIZE YOUR PATIENT'S TREATMENT PLAN AND PROVIDE INSIGHTS INTO FAMILIAL CANCER RISK AND SCREENING REQUIREMENTS

	ASSOCIATED DISEASE RISK							
GENE	BREAST	OVARIAN	ENDOMETRIAL	COLORECTAL	MELANOMA	PANCREATIC	GASTRIC	PROSTATE
APC				X		X	X	
ATM	X	X		X		X		X
AXIN2				X				
BARD1	X							
BMPR1A				X			X	
BRCA1	X	X				X		X
BRCA2	X	X				X		X
BRIP1		X						
CDH1	X						X	
CDK4					X			
CDKN2A					X	X		
CHEK2	X			X				X
EPCAM		X	X	X			X	X
GREM1				X				
HOXB13								X
MLH1		X	X	X		X	X	
MSH2		X	X	X			X	X
MSH3 BIALLELIC				X				
MSH6		X	X	X			X	
MUTYH BIALLELIC				X				
MUTYH MONOALLELIC				X				
NBN		X						X
NTHL1 BIALLELIC	X			X				
PALB2	X	X				X		
PMS2		X	X	X				X
POLD1				X				
POLE				X				
PTEN	X		X	X				
RAD51C	X	X						
RAD51D	X	X						
SMAD4				X			X	
STK11	X	X	X	X		X	X	
TP53	X		X	X	X	X	X	X

To order **Riskguard** and obtain a collection kit, call 855-669-4579 or visit exactsciences.com/riskguard for more information.